Profiling patient-reported symptom recovery from oesophagectomy for patients with oesophageal squamous cell carcinoma: a real-world longitudinal study.
https://doi.org/10.1007/s00520-021-06711-x
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
https://doi.org/10.1097/SLA.0000000000003727
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
miRNA-9 Inhibits Proliferation and Migration of Lung Squamous Cell Carcinoma Cells by Regulating NRSF/EGFR.
https://doi.org/10.1177/1533033820945807
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Genetic Heterogeneity of Esophageal Squamous Cell Carcinoma with Inherited Family History.
https://doi.org/10.2147/OTT.S262512
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma.
https://doi.org/10.1111/nyas.14508
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Response to Comment on "Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus".
https://doi.org/1097/SLA.0000000000004395
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
https://doi.org/10.21037/jgo-20-504
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Preoperative Serum Sodium Level as a Prognostic and Predictive Biomarker for Adjuvant Therapy in Esophageal Cancer.
https://doi.org/10.3389/fonc.2020.555714
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
https://doi.org/10.1097/SLA.0000000000004798
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy.
https://doi.org/10.21037/atm-21-1815
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Identification of tumor-infiltrating lymphocyte subpopulations correlated with patient prognosis in esophageal squamous cell carcinoma.
https://doi.org/10.1177/03000605211016206
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Development and Validation of a Practical Prognostic Coagulation Index for Patients with Esophageal Squamous Cell Cancer.
https://doi.org/10.1245/s10434-021-10239-z
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
https://doi.org/10.1001/jamasurg.2021.2373
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
The impact of adjuvant therapy on survival for node-negative esophageal squamous cell carcinoma: a propensity score-matched analysis.
https://doi.org/10.21037/atm-21-2539
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma.
https://doi.org/10.3389/fonc.2021.711642
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Impact of two‑field or three‑field lymphadenectomy on overall survival in middle and lower thoracic esophageal squamous cell carcinoma: A single‑center retrospective analysis.
https://doi.org/10.3892/ol.2023.13774
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Anti-ageing and Anti-lung Carcinoma Effects of Vulpinic Acid and Usnic Acid Compounds and Biological Investigations with Molecular Modeling Study.
https://doi.org/10.5650/jos.ess21276
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
https://doi.org/10.1093/oncolo/oyab011
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
MLDRL: Multi-loss disentangled representation learning for predicting esophageal cancer response to neoadjuvant chemoradiotherapy using longitudinal CT images.
https://doi.org/10.1016/j.media.2022.102423
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China.
https://doi.org/10.1093/dote/doac031
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Prognostic and incremental value of computed tomography-based radiomics from tumor and nodal regions in esophageal squamous cell carcinoma.
https://doi.org/10.21147/j.issn.1000-9604.2022.02.02
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
https://doi.org/10.3389/fimmu.2022.853922
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Lymph Node Ratio Improves Prediction of Overall Survival in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy: A National Cancer Database Analysis.
https://doi.org/10.1097/SLA.0000000000005450
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010.
https://doi.org/10.1016/j.jtcvs.2022.08.009
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Metastasis to recurrent laryngeal nerve lymph nodes as a predictor of cervical lymph node metastasis in esophageal squamous cell carcinoma.
https://doi.org/10.1016/j.asjsur.2022.09.150
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Nomogram-Based Survival Predictions and Treatment Recommendations for Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Upfront Surgery.
https://doi.org/10.3390/cancers14225567
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
https://doi.org/10.1186/s13014-022-02190-4
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials.
https://doi.org/10.3389/fimmu.2022.1041233
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
Network and pathway-based analysis of genes associated with esophageal squamous cell carcinoma.
https://doi.org/10.21037/atm-22-6512
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023
The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
https://doi.org/10.3389/fimmu.2023.1118902
CHENGDU
Sichuan Cancer Hospital & Institute
Posted on August 3, 2023